Clinical Trial Results:
An 8-week, multicentre, randomised, double-blind, placebo-controlled, flexible dose study of Pregabalin (300-600 mg/day) and Venlafaxine XR (75-225 mg/day) for the acute treatment of DSM-IV Generalized Anxiety Disorder in outpatients.
Summary
|
|
EudraCT number |
2004-001500-13 |
Trial protocol |
IE SE GB ES IT |
Global completion date |
30 Nov 2006
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
29 Jul 2016
|
First version publication date |
29 Jul 2016
|
Other versions |
|
Summary report(s) |
A0081012 Public Disclosure Synopsis |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.